Premium
The role and outcomes of new supraventricular tachycardia among patients with mild heart failure
Author(s) -
Younis Arwa,
Goldenberg Ilan,
McNitt Scott,
Zareba Wojciech,
Kutyifa Valentina,
Aktas Mehmet K.
Publication year - 2020
Publication title -
journal of cardiovascular electrophysiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.193
H-Index - 138
eISSN - 1540-8167
pISSN - 1045-3873
DOI - 10.1111/jce.14416
Subject(s) - medicine , supraventricular tachycardia , heart failure , cardiology , multivariate analysis , ventricular tachycardia , diastole , supraventricular arrhythmia , population , tachycardia , blood pressure , atrial fibrillation , environmental health
We aimed to assess the predictors of new supraventricular tachycardia (SVT) and the association of new SVT with subsequent clinical outcomes among mild heart failure (HF) patients. Methods and Results The study population comprised patients enrolled in MADIT‐CRT, after exclusion of patients with atrial arrhythmias before enrollment (N = 325). Multivariate analysis was used to identify predictors of new‐onset SVT and the association of time‐dependent development of SVT with subsequent ventricular tachyarrhythmic events (VTEs), HF‐hospitalizations, and death. SVT burden was categorized into three groups based on the number of episodes per patient; (a) Low <10, (b) Intermediate ≥10 but <20, and (c) High ≥20. During mean follow up of 3.4 ± 1.1 years, 41(3%) subjects developed new SVT. African American race, diastolic blood pressure (DBP) >80 mmHg and prior non sustained ventricular arrhythmia were independent predictors for SVT. Multivariate analysis showed that the development of time‐dependent SVT was associated with a >4‐fold increased risk for VTEs (HR = 4.3; 95% CI: 1.6‐11.7; P = .004) and with a >6‐fold increased risk for all‐cause mortality (HR = 6.5; 95% CI: 2.3‐18.7; P < .001), but not with HF hospitalizations (HR = 2.2; 95% CI: 0.7‐7.2; P = .17). Intermediate, and high SVT‐burden were each independent risk factors for death when compared with Low burden (HR = 9.1; P = .03, and HR = 19.4; P < .001; respectively). Conclusions In patients with mild HF, the development of new‐onset SVT after device implantation is related to distinct baseline clinical and epidemiologic characteristics and is associated with a significant increase in subsequent adverse outcomes, including VTEs and death.